Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Net Cash Flow data on file, last reported at -$246.0 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$246.0 million, down 436.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.8 million (up 173.28% YoY), and the FY2025 annual result was $248.0 million, up 851.52% from the prior year.
• Net Cash Flow retreated to -$246.0 million in Q1 2026 per RARE's latest filing, from $222.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $368.5 million in Q2 2024 and troughed at -$331.3 million in Q3 2024.
• A 5-year average of -$7.1 million and a median of $7.7 million in 2022 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 2164.18% in 2024 and fell as far as 1068.89% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$260.1 million in 2022, then surged by 153.59% to $139.4 million in 2023, then tumbled by 81.25% to $26.1 million in 2024, then surged by 749.94% to $222.1 million in 2025, then tumbled by 210.75% to -$246.0 million in 2026.
• Business Quant data shows RARE's Net Cash Flow at -$246.0 million in Q1 2026, $222.1 million in Q4 2025, and $25.8 million in Q3 2025.